Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to
Clipboard
My Bibliography
Collections
Citation manager
Display options Display options Format Abstract PubMed PMID
Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel
Add to Collections
Create a new collection
Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel
Add to My Bibliography
My Bibliography
Unable to load your delegates due to an error Please try again Add Cancel
Your saved search
Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons
Yes
No
Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel
Create a file for external citation management software
Create file Cancel
Your RSS Feed
Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy
Full text links
Silverchair Information Systems Free PMC article Full text links
Actions
CiteCollectionsAdd to Collections
Create a new collection
Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel PermalinkPermalinkCopyDisplay options Display options Format AbstractPubMedPMID
Page navigation
Title & authors
Abstract
Figures
Comment in
References
Publication types
MeSH terms
LinkOut - more resources
Title & authors Abstract Figures Comment in References Publication types MeSH terms LinkOut - more resources Full text links CiteDisplay options Display options Format AbstractPubMedPMID
Abstract
Mediastinal large B-cell lymphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients ≤ 18 years of age. We analyzed data from childhood and adolescent patients with stage III MLBL (n = 42) and non-MLBL DLBCL (n = 69) treated with Group B therapy in the French-American-British/Lymphome Malins de Burkitt (FAB/LMB) 96 study. MLBL patients had a male/female 26/16; median age, 15.7 years (range, 12.5-19.7); and LDH < 2 versus ≥ 2 × the upper limit of normal, 23:19. Six MLBL patients (14%) had < a 20% response to initial COP (cyclophosphamide, vincristine, and prednisone) therapy. Central pathology revealed approximately 50% with classical features of primary MLBL. Five-year event-free survival for the stage III MLBL and non-MLBL DLBCL groups was 66% (95% confidence interval [CI], 49%-78%) and 85% (95% CI, 71%-92%), respectively (P < .001; 14%). The 5-year overall survival in the 42 MLBL patients was 73% (95% CI, 56%-84%). We conclude that MLBL in adolescent patients is associated with significantly inferior event-free survival compared with stage III non-MLBL DLBCL and can be of multiple histologies. Alternate treatment strategies should be investigated in the future taking into account both adult MLBL approaches and more recent biologic findings in adult MLBL.
PubMed Disclaimer
Figures
Figure 1
Main deregulated signaling pathways in…
Figure 1
Main deregulated signaling pathways in PMBCL. Shown are the main activation cascades of… Figure 1 Main deregulated signaling pathways in PMBCL. Shown are the main activation cascades of JAK-STAT and NF-κB signaling. Alternative pathway activation exists. Known gene alterations leading to constitutive pathway activity in PMBCL are shown in color. Reprinted from Steidl and Gascoyne by permission of the American Society of Hematology.
Figure 2
Pathologic features of mediastinal large-cell…
Figure 2
Pathologic features of mediastinal large-cell lymphoma. (A) H&E histologic section of a MLBL… Figure 2 Pathologic features of mediastinal large-cell lymphoma. (A) H&E histologic section of a MLBL tumor showing the characteristic large-cell infiltrate with intervening bands of compartmentalizing fibrosis. The tumor cells form individual cells and small groups (400× magnification). (B) CD20 immunoperoxidase staining demonstrating the mature MLBL infiltrate (1000× magnification). (C) IRF4/MUM 1 staining of a MLBL tumor showing characteristic nuclear staining (100× magnification; Olympus BX40 microscope).
Figure 3
Treatment course for each MLBL…
Figure 3
Treatment course for each MLBL patient treated in the FAB/LMB 96 study. All… Figure 3 Treatment course for each MLBL patient treated in the FAB/LMB 96 study. All MLBL patients received Group B therapy initially. After the COP reduction phase, patients with a CR or intermediate response (defined as a 20%-99% reduction in the product of the 2 largest diameters of evaluable lesions) continued on Group B therapy. At the third evaluation, a CR included residual masses as long as adequate biopsy demonstrated no viable tumor. Patients with residual viable tumors (persistent disease) were switched to Group C therapy beginning with CYVE1 consolidation. Nine patients in CR continued onto Group C M1-M4 therapy, 1 patient from Group B and 8 patients from Group C. Patients with disease progression (> 25% increase in the product of 2 largest diameters) were taken off study. Disease status at last follow-up for all patients completing therapy is included.
Figure 4
Probability of 5-year EFS and…
Figure 4
Probability of 5-year EFS and OS calculated using the Kaplan-Meier method for MLBL… Figure 4 Probability of 5-year EFS and OS calculated using the Kaplan-Meier method for MLBL patients treated on Group B therapy in the FAB/LMB 96 study.
Figure 5
Probability of 5-year EFS calculated…
Figure 5
Probability of 5-year EFS calculated using the Kaplan-Meier method for patients with MLBL… Figure 5 Probability of 5-year EFS calculated using the Kaplan-Meier method for patients with MLBL compared with stage III non-MLBL DLBCL patients treated on Group B therapy in the FAB/LMB 96 study. The 5-year EFS for MLBL patients was 66% (95% CI, 49%-78%) and for stage III non-MLBL DLBCL patients, it was 85% (95% CI, 71%-92%; P < .001). See this image and copyright information in PMC
Comment in
Pediatric MLBL: challenges remain. Sandlund JT, Choi JK.Sandlund JT, et al.Blood. 2013 Jan 10;121(2):245-6. doi: 10.1182/blood-2012-11-468629.Blood. 2013.PMID: 23307971
References
Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Vol 3. Lyon, France: International Agency for Research on Cancer; 2001.
Swerdlow S, Campo E, Harris NL, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008. International Agency for Research on Cancer. pp. 1–439.
Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–339. - PubMed
Lones MA, Perkins SL, Sposto R, et al. Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol. 2000;18(22):3845–3853. - PubMed
Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 2003;21(9):1782–1789. - PubMed
Lymphoma, Large B-Cell, Diffuse / drug therapy* Actions
Search in PubMed
Search in MeSH
Add to Search
Lymphoma, Large B-Cell, Diffuse / mortality Actions
Search in PubMed
Search in MeSH
Add to Search
Lymphoma, Large B-Cell, Diffuse / pathology* Actions
Search in PubMed
Search in MeSH
Add to Search
Male Actions
Search in PubMed
Search in MeSH
Add to Search
Mediastinal Neoplasms / drug therapy* Actions
Search in PubMed
Search in MeSH
Add to Search
Mediastinal Neoplasms / mortality Actions
Search in PubMed
Search in MeSH
Add to Search
Mediastinal Neoplasms / pathology* Actions
Search in PubMed
Search in MeSH
Add to Search
Neoplasm Staging Actions
Search in PubMed
Search in MeSH
Add to Search
Treatment Outcome Actions
Search in PubMed
Search in MeSH
Add to Search
LinkOut - more resources
Full Text Sources
Elsevier Science
Europe PubMed Central
PubMed Central
Silverchair Information Systems
Other Literature Sources
scite Smart Citations
Miscellaneous
NCI CPTAC Assay Portal
Full text links [x] Silverchair Information Systems Free PMC article [x] Cite Copy Download .nbib.nbib Format: AMA APA MLA NLM Send To
Clipboard
Email
Save
My Bibliography
Collections
Citation Manager
[x]
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Search: Search Advanced Clipboard Save Email Send to
Silverchair Information Systems Free PMC article Full text links 
